Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 13 of 58, showing 10 Applications out of 576 total, starting on record 121, ending on 130

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

121.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
28-07-2016 View

122.

ECCT/16/06/02   A5263: A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings
     A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings   
Principal Investigator(s)
1. Vincent Oliver Otieno
Site(s) in Kenya
1. Kisumu CRS (Kisumu county)
 
28-07-2016 View

123.

ECCT/16/08/02   Zeenk study
    Zeenk Acceptability Study   
Principal Investigator(s)
1. Margaret Oluka
2. David Kimutai
3. Caren Emadu
Site(s) in Kenya
1. Mbagathi District Hospital (Nairobi City county)
2. Mama Lucy Kibaki Hospital (Nairobi City county)
 
10-08-2016 View

124.

ECCT/16/07/01   VAC52150EBL4001
    A Multi-country, prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines AD26.ZEBOV and or/ MVA-BN-Filo   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Kenya medical Research Institute/Walter Reed Project Kombewa (Kisumu county)
3. Kenya medical Research Institute/Walter Reed Project Kombewa (Kericho county)
 
15-08-2016 View

125.

ECCT/16/07/02   A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events
    A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events   
Principal Investigator(s)
1. Mark Loeb
Site(s) in Kenya
The Aga Khan University Hospital
 
17-08-2016 View

126.

ECCT/16/05/02   Monitoring Pre-exposure Prophylaxis for Young Adult women (MPYA)
    Next generation real-time monitoring for PrEP adherence in young Kenyan women   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. Thika Partners Study Clinic (Partners in Health Research and Development) (Kiambu county)
2. Partners in Prevention, Kisumu Site (Kisumu county)
 
07-09-2016 View

127.

ECCT/16/07/05   HESTIA 1
    Multicentre, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease   
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Kemri CRDR research center at Chandaria Health Centre Dagoretti (Nairobi City county)
3. Clinical Research Annex at the Siaya County Referral Hospital (Siaya county)
4. Kondele Children’s Hospital, KEMRI – Centre for Clinical Research (Kisumu county)
 
19-09-2016 View

128.

ECCT/16/09/02   Monitoring Pre-Exposure Prophylaxis for Young Adult Women ( (MPYA)
    Next generation real-time monitoring for PrEP adherence in young adult women.   
Principal Investigator(s)
1. Prof. Elizabeth Anne Bukusi Bukusi
2. Dr. Stella Njuguna Njuguna
Site(s) in Kenya
1. KISUMU SITE (Kisumu county)
 
27-09-2016 View

129.

ECCT/16/07/06   Cups or Cash for Girls Trial
    Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in adolescent schoolgirls in western Kenya: a cluster randomised controlled trial   
Principal Investigator(s)
1. Penelope Anne Phillips-Howard
2. Daniel Oluoch Kwaro
Site(s) in Kenya
Siaya County
 
19-10-2016 View

130.

ECCT/16/08/03   IMPAACT 2001
    A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed project
 
27-10-2016 View